Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65


Adherence biomarker measurements in older and younger HIV-infected adults receiving tenofovir-based therapy.

Seifert SM, Castillo-Mancilla JR, Erlandson K, Morrow M, Gandhi M, Kuncze K, Horng H, Zheng JH, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL.

J Acquir Immune Defic Syndr. 2017 Nov 17. doi: 10.1097/QAI.0000000000001596. [Epub ahead of print]


Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.

Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S.

Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01710-17. doi: 10.1128/AAC.01710-17. [Epub ahead of print]


Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.

MacBrayne CE, Castillo-Mancilla J, Burton JR Jr, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ.

J Antimicrob Chemother. 2017 Oct 4. doi: 10.1093/jac/dkx344. [Epub ahead of print]


Cell-line dependent antiviral activity of sofosbuvir against Zika virus.

Mumtaz N, Jimmerson LC, Bushman LR, Kiser JJ, Aron G, Reusken CBEM, Koopmans MPG, van Kampen JJA.

Antiviral Res. 2017 Oct;146:161-163. doi: 10.1016/j.antiviral.2017.09.004. Epub 2017 Sep 11.


Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.

Kiser JJ, Lu D, Rosenkranz SL, Morse GD, DiFrancesco R, Sherman KE, Butt AA; ACTG A5309s study team.

Drugs R D. 2017 Dec;17(4):557-567. doi: 10.1007/s40268-017-0205-9.


Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.

Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM.

JAMA Pediatr. 2017 Nov 1;171(11):1063-1071. doi: 10.1001/jamapediatrics.2017.2007.


Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.

Naggie S, Marks KM, Hughes M, Fierer DS, Macbrayne C, Kim A, Hollabaugh K, Roa J, Symonds B, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Chung R; AIDS Clinical Trials Group (ACTG) A5327 Study Team.

Clin Infect Dis. 2017 Apr 15;64(8):1035-1042. doi: 10.1093/cid/cix025.


Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.

Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ.

World J Gastroenterol. 2017 Mar 7;23(9):1618-1626. doi: 10.3748/wjg.v23.i9.1618.


Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.

Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA, The Actg Birth Study Team.

World J Hepatol. 2017 Feb 8;9(4):217-223. doi: 10.4254/wjh.v9.i4.217.


Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.

Jimmerson LC, Clayton CW, MaWhinney S, Meissner EG, Sims Z, Kottilil S, Kiser JJ.

Antiviral Res. 2017 Feb;138:79-85. doi: 10.1016/j.antiviral.2016.12.005. Epub 2016 Dec 9.


Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.

Chen X, Seifert SM, Castillo-Mancilla JR, Bushman LR, Zheng JH, Kiser JJ, MaWhinney S, Anderson PL.

PLoS One. 2016 Nov 10;11(11):e0165505. doi: 10.1371/journal.pone.0165505. eCollection 2016.


A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Jimmerson LC, Bushman LR, Ray ML, Anderson PL, Kiser JJ.

Pharm Res. 2017 Jan;34(1):73-83. doi: 10.1007/s11095-016-2040-z. Epub 2016 Sep 15.


An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.

Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G, Lally M, Mayer KH, Anderson P, Kiser J, Rooney JF, Wilson CM; Adolescent Trials Network (ATN) for HIVAIDS Interventions.

J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):21-29.


Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Clayton C, Austin G, Palmer BE, Zheng JH, Klein B, Kerr BJ, Guida LA, Rower C, Rower JE, Kiser JJ, Bushman LR, MaWhinney S, Anderson PL.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):981-991. Epub 2016 Sep 19.


Role of Transporters in Drug Development.

Arya V, Kiser JJ.

J Clin Pharmacol. 2016 Jul;56 Suppl 7:S7-S10. doi: 10.1002/jcph.784. No abstract available.


Effect of Disease Pathologies on Transporter Expression and Function.

Atilano-Roque A, Roda G, Fogueri U, Kiser JJ, Joy MS.

J Clin Pharmacol. 2016 Jul;56 Suppl 7:S205-21. doi: 10.1002/jcph.768. Review.


Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.

MacBrayne CE, Kiser JJ.

Clin Infect Dis. 2016 Jul 15;63 Suppl 1:S12-23. doi: 10.1093/cid/ciw220. Erratum in: Clin Infect Dis. 2016 Sep 1;63(5):715.


Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.

Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, Kottilil S, Meissner EG, Sims Z, Langness JA, Hodara A, Aquilante CL, Kiser JJ.

J Clin Pharmacol. 2017 Jan;57(1):118-124. doi: 10.1002/jcph.783. Epub 2016 Aug 4.


Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients.

Fuchs EJ, Kiser JJ, Hendrix CW, Sulkowski M, Radebaugh C, Bushman L, Ray ML, Andrade A.

J Antimicrob Chemother. 2016 Jun;71(6):1597-600. doi: 10.1093/jac/dkw009. Epub 2016 Feb 10.

Supplemental Content

Loading ...
Support Center